SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreem...
GYEONGGI, South Korea, Feb. 14, 2019 /PRNewswire-AsiaNet/ -- -- Arvelle Therapeutics to receive rights to develop and commercialize cenobamate, an investigational antiepileptic drug developed by SK Biopharmaceuticals, in Europe-- SK Biopharmaceuticals to receive upfront payment of $100 million and will ...
Authors: LATEST ASIANET NEWS RELEASES